894783-61-0

Basic information

• Product Name: Nintedanib impurity G
• Synonyms: Nintedanib impurity G;Intedanib Impurity G
• CAS NO: 894783-61-0
• Molecular Formula: C30H31N5O4
• Molecular Weight: 525.6
• Mol File: 894783-61-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Nintedanib impurity G(CAS DataBase Reference)
• NIST Chemistry Reference: Nintedanib impurity G(894783-61-0)
• EPA Substance Registry System: Nintedanib impurity G(894783-61-0)

Safety Data

• Hazardous Substances Data: 894783-61-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Nintedanib impurity G is used as a research compound for studying the synthesis of indolinones as triple angiokinase inhibitors. This application is significant in the development of novel antitumor agents and understanding the mechanisms of action of Intedanib.
In the context of the provided materials, Nintedanib impurity G's primary use is in the pharmaceutical industry, specifically for research purposes related to the development of antitumor agents and the study of angiokinase inhibitors.

Upstream product

• 262368-25-2 N-(4-aminophenyl)-2-(4-methylpiperazin-1-yl)acetamide 
• 1168152-07-5 (E)-1-acetyl-3-(methoxy-phenyl-methylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester 

Relevant articles and documents

Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)

Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a newtreatment modality in oncology. Preclinical findings suggest that blockade of additional pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor receptors (FGFR and PDGFR), may improve the efficacy of pharmacological cancer treatment. Indolinones substituted in position 6 were identified as selective inhibitors of VEGF-, PDGF-, and FGF-receptor kinases. In particular, 6-methoxycarbonyl-substituted indolinones showed a highly favorable selectivity profile. Optimization identified potent inhibitors of VEGF-related endothelial cell proliferation with additional efficacy on pericyctes and smooth muscle cells. In contrast, no direct inhibition of tumor cell proliferation was observed. Compounds 2 (BIBF 1000) and 3 (BIBF 1120) are orally available and display encouraging efficacy in in vivo tumor models while being well tolerated. The triple angiokinase inhibitor 3 is currently in phase III clinical trials for the treatment of nonsmall cell lung cancer.

Medicaments for the Treatment or Prevention of Fibrotic Diseases

The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.